The release of FDA’s draft guidance, “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases,” has been greatly anticipated since June 2021, when FDA announced in its accelerated approval of the KRASG12C inhibitor sotorasib that it would require a randomized, controlled trial comparing the efficacy of the labeled dose (960 mg once daily) to a 75% lower dose (240 mg once daily) as a condition of full regulatory approval (The Cancer Letter, June 11, 2021; April 29, 2022).
Duke Cancer Institute is commemorating 50 years of gynecologic care and research.
When you hear the words “world famous scientist,” “devoted parent and husband,” “enthusiastic mentor,” and “committed friend,” who comes to mind? I, like many others across the world, think of Dr. C. David Allis. David, a prolific scientist, with over 400 publications and more than 100,000 citations, made many discoveries that have shaped our understanding about how genes are regulated and made a full circle bench-to-bedside impact.
In January, the Cancer History Project is focusing on the legacies of the people who comprise the field. A full archive of individuals whose contributions are preserved in the Cancer History Project is available here.
When Kay Dickersin was diagnosed with breast cancer in 1986, the support group available to her in Baltimore focused largely on how to get the makeup and wig to look right.
In an interview with the Cancer History Project, Kay Dickersin, one of the early leaders of the grassroots breast cancer patient advocacy movement, recounted the beginnings of the National Breast Cancer Coalition.
The year of 2022 was probably the most challenging and hard for Ukraine since the start of our independence. Our lives have changed significantly as we are fighting for the world’s freedom and democracy. In these circumstances, the Ukrainian healthcare system remained stable and doctors kept doing their job at hospitals around the country, including oncologists who did their best to treat patients in any way possible.
In 1971, when the National Cancer Act was signed, J. Palmer Saunders was the director of the Division of Cancer Research, Resources and Centers.
S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.
Steady advancements in cancer treatments over the past century have led to significant improvements in the expected lifespan of cancer patients. However, to this day, cancer is very rarely cured.
